Khiron Life Sciences (TSXV: KHRN) announced this morning that it has received authorization from the Colombian government to begin selling high-THC medical cannabis to patients. Khiron is the first, and currently only, company to receive authorization from the Colombian government for both the manufacturing and sale of high-THC medical cannabis.
The company itself refers to the authorization as having been for “magistral preparation” for high-THC medical cannabis, a term which is defined as “any medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient.” The authorization enables the company to immediately begin selling high-THC medical products through its ILAN pharmacy network.
ILAN is fully authorized to sell high-THC products to patients for indications that include nausea, chronic pain, and vomiting associated with chemotherapy. Expanded distribution is expected to also occur as partner pharmacies receive approval to sell high-THC medical cannabis to patients, with the company giving a target of the third quarter of 2020 for this expanded distribution.
Khiron Life Sciences last traded at $0.82 on the TSX Venture.
FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.